Open AccessA multicenter, randomized, equivalence trial of a new recombinant human chorionic gonadotropin preparation versus ovitrelle® for ovulation in women undergoing intrauterine insemination following ovarian stimulation
Author(s) -
Abha Majumdar,
Rekha Sachan,
Y. S. Nandanwar,
Rahul Mayekar,
Neelu Soni,
Manish Banker,
Rajan S Vaidya,
Manjeet Arora,
Girish Godbole,
Gautam V. Daftary,
Ganesh Divekar,
James Rufus John
Publication year - 2019
Publication title -
journal of human reproductive sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.484
H-Index - 31
eISSN - 0974-1208
pISSN - 1998-4766
DOI - 10.4103/jhrs.jhrs_101_18
Subject(s) - ovulation induction , medicine , ovulation , human chorionic gonadotropin , gynecology , gonadotropin , pregnancy rate , pregnancy , artificial insemination , andrology , insemination , obstetrics , biology , hormone , sperm , genetics
A new indigenous recombinant human chorionic gonadotropin (r-hCG) has been developed in India with a comparable pharmacological profile to that of Ovitrelle ® (Merck Serono).